Agilent Inks Sequence-Enrichment Deal with Life Tech; Says Varian Acquisition is on Track

An Agilent official who disclosed the agreement at the UBS Global Life Sciences Conference also noted that the company's proposed $1.5 billion acquisition of Varian is on track to be completed by the end of the year.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.